Slide 1: SUVEN Life Sciences Communication to investors
SUVEN Life Sciences Communication to investors Mar 2019 25-May-19 2018-19 Q4 results
Slide 2: Risk statement
Risk statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Financial Quick View Quarter 4 – Mar 2019
FINANCIAL QUICK VIEW Quarter 4 – Mar 2019 • Growth in income 90.72% • Growth in Pre-R&D EBIDTA 129.13% • Growth in EBIDTA 163.66% • Growth in PAT 170.41% • R&D cost on revenue 6.95% • Increase in R&D costs 27.35% 25-May-19 2018-19 Q4 results
Slide 4: Financial Quick View Year ending – Mar 2019
FINANCIAL QUICK VIEW Year ending – Mar 2019 • Growth in income 6.05% • Growth in Pre-R&D EBIDTA -2.10% • Growth in EBIDTA -3.29% • Growth in PAT -5.20% • R&D cost on revenue 8.76% • Increase in R&D costs 3.09% 25-May-19 2018-19 Q4 results
Slide 5: Major Profitability Ratios
MAJOR PROFITABILITY RATIOS Q4 Mar 19 FY Mar 19 Pre-R&D 49.37% 44.79% EBITDA to Income EBIDTA to 42.42% 36.03% Income PAT to 26.47% 21.80% Income Cash Flow to 28.60% 25.02% Income 25-May-19 2018-19 Q4 results
Slide 6: Q4 to Q3 Comparison
Q4 to Q3 COMPARISON Current quarter to previous quarter Revenue - INR Million PAT - INR Million 3,100.00 800.00 2,570.53 680.47 2,600.00 700.00 600.00 2,100.00 500.00 1,600.00 1,347.83 400.00 300.00 251.65 1,100.00 200.00 600.00 100.00 100.00 - Q3 Dec 18 Q4 Mar 19 Q3 Dec 18 Q4 Mar 19 EBIDTA - INR Mi
Slide 7: Income Comparison
INCOME COMPARISON Year on year INR Million 8,000.00 6,877.34 7,000.00 6,485.29 6,000.00 5,000.00 4,000.00 3,000.00 2,570.53 2,229.49 2,000.00 1,000.00 - Q4 Mar 18 Q4 Mar 19 FY Mar 18 FY Mar 19 25-May-19 2018-19 Q4 results
Slide 8: Profit Comparison
PROFIT COMPARISON Year on year INR Million 1,800.00 1,581.51 1,600.00 1,499.25 1,400.00 1,200.00 1,000.00 800.00 680.47 623.07 600.00 400.00 200.00 - Q4 Mar 18 Q4 Mar 19 FY Mar 18 FY Mar 19 25-May-19 2018-19 Q4 results
Slide 9: EBIDTA Comparison
EBIDTA COMPARISON Year on year INR Million 3,000.00 2,561.87 2,477.71 2,500.00 2,000.00 1,500.00 1,090.48 1,004.68 1,000.00 500.00 - Q4 Mar 18 Q4 Mar 19 FY Mar 18 FY Mar 19 25-May-19 2018-19 Q4 results
Slide 10: R & D – Expenditure
R & D – EXPENDITURE Year on year INR Million 700.00 602.76 600.00 584.67 500.00 400.00 300.00 200.00 169.15 178.69 100.00 - Q4 Mar 18 Q4 Mar 19 FY Mar 18 FY Mar 19 25-May-19 2018-19 Q4 results
Slide 11: Pre-R&D EBIDTA
PRE-R&D EBIDTA Year on year INR Million 3,500.00 3,146.53 3,080.47 3,000.00 2,500.00 2,000.00 1,500.00 1,269.17 1,173.83 1,000.00 500.00 - Q4 Mar 18 Q4 Mar 19 FY Mar 18 FY Mar 19 25-May-19 2018-19 Q4 results
Slide 12: Pre-R&D Cashflow
PRE-R&D CASHFLOW Year on year INR Million 2,500.00 2,379.27 2,323.42 2,000.00 1,500.00 1,000.00 913.79 845.84 500.00 - Q4 Mar 18 Q4 Mar 19 FY Mar 18 FY Mar 19 25-May-19 2018-19 Q4 results
Slide 13: Financial Snapshot
Financial Snapshot All figures are in INR Million, other than ratios and EPS Standalone Consolidated Q4 - FY19 Q3 - FY19 Q4 - FY18 2018-19 2017-18 2018-19 2017-18 Income 2,571 1,348 2,229 6,877 6,485 6,877 6,485 Pre-R&D EBITDA 1,269 554 1,174 3,080 3,147 3,045 3,117 Pre-R&D EBITDA Margin 49.37% 41.1
Slide 14: News Release
News Release • Marupirdine (SUVN-502) Phase 2A clinical trial, indicated for patients with moderate Alzheimer’s initiated in 76 investigator sites in USA and completed clinical trial with the last patient last visit (LPLV) in May 2019. • Top-line Phase 2A data for Masupirdine (SUVN-502) is on track